ALLO (Allogene Therapeutics) Change In Inventory: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALLO Allogene Therapeutics Inc ALLO
32 GF Score
Price $2.08
! 3 Warning Signs
View Full Analysis

What is Allogene Therapeutics Change In Inventory?

Allogene Therapeutics ALLO +3.23% 32 Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus rates ALLO with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Allogene Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Allogene Therapeutics's inventory stayed the same from Dec. 2025 to Mar. 2026 .

Allogene Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Allogene Therapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Allogene Therapeutics's Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allogene Therapeutics  (NAS:ALLO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Allogene Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Allogene Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allogene Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allogene Therapeutics Change In Inventory Related Terms

Allogene Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Allogene Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allogene Therapeutics Change In Inventory Chart

Allogene Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Allogene Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ALLO
32GF Score
Allogene Therapeutics Inc ALLO
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allogene Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $0.00 Mil mean?
Allogene Therapeutics (ALLO) has a Change In Inventory of $0.00 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Allogene Therapeutics and its competitors.
Is Allogene Therapeutics' Change In Inventory too high?
Allogene Therapeutics' current Change In Inventory is $0.00 Mil. Overall, Allogene Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Allogene Therapeutics' Change In Inventory compare to CBIO and IMMX?
Allogene Therapeutics' Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Allogene Therapeutics and its competitors. Allogene Therapeutics's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allogene Therapeutics stock overvalued right now?
Allogene Therapeutics (ALLO) has a current Change In Inventory of $0.00 Mil. The current Change In Inventory is $0.00 Mil. Allogene Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Allogene Therapeutics (ALLO), the current Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allogene Therapeutics Business Description

Address 210 East Grand Avenue, South San Francisco, CA, USA, 94080
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
32GF Score

Get the complete analysis for ALLO

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price